For example, to address resistance to SMOis in patients with BCC and medulloblastomas (4, 5, 13), second-line therapies inhibiting downstream activators of the SHH pathway, such as GLI, are being investigated (37, 51). Here, GLI1 is linked to medulloblastoma.